Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02607800 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
A Phase 3 study of Hepatitis C, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 943
- Enrollment target
- 20
- Study locations
NCT02607800: Completed Phase 3 study of Hepatitis C, sponsored by Gilead Sciences.
NCT02607800 is a Phase 3 study of Hepatitis C that has completed, run by Gilead Sciences. The registered enrollment target is 943 participants, below the 1,881-participant average among 106 other Hepatitis C trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02607800, a Phase 3 study of Hepatitis C, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 943 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this study are to compare the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) for 8 weeks with that of SOF/VEL FDC for 12 weeks in direct-acting antiviral-naive participants with chronic hepatitis C virus (HCV) infection.
Primary Outcome
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.
Conditions Studied
Interventions
- DRUG SOF/VEL/VOX
- DRUG SOF/VEL
Study Locations (20)
California
- - Long Beach
- - Los Angeles
- - Palo Alto
- - Pasadena
- - Rialto
- - San Diego
- - San Francisco
Florida
- - Gainesville
- - Miami
- - Orlando
- - Wellington
Colorado
- - Aurora
- - Englewood
Georgia
- - Atlanta
- - Marietta
District of Columbia
- - Washington D.C.
Illinois
- - Chicago
Indiana
- - Indianapolis
Louisiana
- - Bastrop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 943 participants |
| Start Date | 2015-11-16 |
| Est. Completion | 2017-01-11 |
| Phase | Phase 3 |
What the finished NCT02607800 record still lists
NCT02607800 is an interventional study that assigns participants to a tested intervention. The registered 943 participants enrollment target is mid-sized for trials with a published cap, below the 1,881-participant average among 106 other Hepatitis C trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which SOF/VEL/VOX is the first listed.
NCT02607800 names 20 study sites across 9 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT02607800 about?
NCT02607800 is a clinical study titled "Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy". The primary objectives of this study are to compare the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) for 8 weeks with that of SOF/VEL FDC for 12 weeks in direct-acting antiviral-naive participants with chronic hep...
What is the current status of trial NCT02607800?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 943 participants. The study started on 2015-11-16. Estimated completion is 2017-01-11.
What conditions does trial NCT02607800 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT02607800?
The interventions under investigation include: SOF/VEL/VOX (DRUG), SOF/VEL (DRUG).
Who is sponsoring clinical trial NCT02607800?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02607800 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02607800's enrollment target sits among peer trials
943 8th of 106 higher than 99 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
COMPLETED · Phase 3
-
SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection
COMPLETED · Phase 3
-
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
COMPLETED · Phase 3
-
Hepatitis C Antiviral Resistance in African-Americans
COMPLETED · Phase 3
-
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 3
-
An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI